I'll be presenting at the @nusl.bsky.social Annual Health Law Conference in Boston on April 3rd, on a panel titled "The Regulatory Environment and the FDA." Looking forward to the discussion with co-panelists @sbagen.bsky.social and @rachelsachs.bsky.social and moderator @davidasimon.bsky.social!

Please join us on March 27th at @slulaw.bsky.social for the @sluhealthlaw.bsky.social 38th Annual Health Law Symposium, "A Defining Moment for Vaccine Science and Policy" Schedule here: www.slu.edu/law/health/s... Register to attend (in person or via Zoom) here: docs.google.com/forms/d/e/1F...

At the American College of Legal Medicine meeting @asulaw.bsky.social -- presented on the "Updates in FDA Law" panel with @medlawdan.bsky.social @sjquinney.bsky.social and Dr. Jack Snyder

The article traces weight loss medication history & #obesity stigma, noting a shift from personal blame to disease recognition, & argues that new drugs could reduce barriers & stigma. Read: spkl.io/63328AvH5p Subscribe: spkl.io/63322AvH5k#obesity #LawSky @drsinhaesq.bsky.social

Please join us on March 27th at @slulaw.bsky.social for the @sluhealthlaw.bsky.social 38th Annual Health Law Symposium, "A Defining Moment for Vaccine Science and Policy" Schedule here: www.slu.edu/law/health/s... Register to attend (in person or via Zoom) here: docs.google.com/forms/d/e/1F...

Terrific guest lecture by @ghorvath.bsky.social @uclawsf.bsky.social to my Drug and Device Regulation and Innovation seminar at @slulaw.bsky.social @sluhealthlaw.bsky.social on Tuesday, focused on Incremental Innovation in medical devices. Article here: scholar.smu.edu/scitech/vol2...

Catch that #$NVS ad last night? It is a form of unbranded advertising. Novartis wants men to have their PSA levels checked because the company is heavily invested in prostate cancer therapies.

I am far less confident than Novo's chief counsel that their patent will not be invalidated. Recent actions by FDA/HHS/DOJ are much more likely to protect the company's prized asset #Wegovy.

Really enjoyed having @davidasimon.bsky.social @nusl.bsky.social join my "Drug and Device Regulation and Innovation" seminar today at @slulaw.bsky.social @sluhealthlaw.bsky.social to discuss his ongoing work on medical device safety (www.safemedicaldevices.org) and Data Distortions with the class!

Submissions for the 2026 #HealthLaw Scholars Workshop are being accepted now through April 13. The strength of the workshop relies on a strong pool of submissions, so please share this call widely. Excited to celebrate our 25th year with four excellent new scholars! www.slu.edu/law/health/s...

Pleased to be listed in @heinonline.bsky.social's Scholarly Impact Rankings for Food and Drug Law! heinonline.org/HOL/scholarl...

#FenwayPark in June

Cites my piece from the Journal of Law and the Biosciences with Lisa Verity and Ana Santos Rutschman: The pressing need for FDA regulation of tattoo ink academic.oup.com/jlb/article/... Glad to see that FDA now has guidance for industry on tattoo ink safety (Oct. 2024): www.fda.gov/regulatory-i...

Nice to see industry pushing back, akin to its response to right-to-try. Essentially, "no thanks, we prefer the status quo."

Thrilled to share that I was selected to be a Fellow of @amwadoctors.bsky.social, a program that "serves to recognize and honor distinguished members of #AMWA who have accomplished outstanding achievements in science, medicine, or academia." amwa-doc.org/members/phys... cc: @sluhealthlaw.bsky.social

Read @elaineywchen.bsky.social's write-up of former top FDA drug regulator Rick Pazdur's explosive panel at STAT's event at #JPM2026 last night, moderated by @matthewherper.bsky.social. Drug makers should be more concerned by what's happening at FDA, Pazdur said. www.statnews.com/2026/01/13/r...

This semester at @slulaw.bsky.social @sluhealthlaw.bsky.social, I will be teaching Patent Law and a seminar on Drug and Device Innovation. Looking forward to it!

Now published in @uchilegalforum.bsky.social -- Vaccines for Pandemics: Lessons from COVID-19 for H5N1 and Beyond (with Alison McCarthy, SLU LAW '25) legal-forum.uchicago.edu/sites/defaul... cc: @slulaw.bsky.social @sluhealthlaw.bsky.social @ciclslulaw.bsky.social

💬 Viewpoint: Combination-only approvals for new #HIV drugs limit generic substitution and sustain high antiretroviral prices, even after key patents expire. ja.ma/4jw2Dqz

Check out our article, "Combination-Only Approvals as a Barrier to Affordable HIV Care," in this week's issue of @jama.com: jamanetwork.com/journals/jam... cc: @sluhealthlaw.bsky.social @slulaw.bsky.social @portalresearch.org @dartmouthchem.bsky.social

Now in print in this week's issue of @jama.com!

New @jama.com article written by @medlawdan.bsky.social, @drsinhaesq.bsky.social, and I. Glenn Cohen examines the FDA’s plan to approve leucovorin for some patients with autism using evidence that departs from traditional regulatory standards jamanetwork.com/journals/jam...

A lot has happened at FDA since we wrote this piece in @jama.com, but leucovorin was a harbinger of things to come.

Also my life right now. #Torts

"If high-level officials at the FDA are interested in the new use of a drug, they should lead with evidence, not with approval, and outline a process to ensure decisional integrity."

💬 Viewpoint: Approval of leucovorin for cerebral folate deficiency based on limited evidence raises concerns about weakening FDA drug approval standards and public trust. ja.ma/4asLxYh

NEW: Paper in @jama.com (me, Glenn Cohen, & @drsinhaesq.bsky.social) discusses FDA plan to approve leucovorin for new indication based on "case reports" and "mechanistic data" 1. Departure from FDA's evidentiary standards 2. May harm patients and set bad precedent jamanetwork.com/journals/jam...

Nice review of my AJLM article with Joseph DaVault (@slulaw.bsky.social '24) on lab grown meat www.theregreview.org/2025/12/17/a... via @theregreview.bsky.social cc: @sluhealthlaw.bsky.social

💬 Viewpoint: Combination-only approvals for new #HIV drugs limit generic substitution and sustain high antiretroviral prices, even after key patents expire. #WorldAIDSDay2025 ja.ma/4pwRTKi

Officially out in UC Irvine Law Review: Unpatenting Product Hops! escholarship.org/uc/item/0kg3... Bittersweet, as it shares an issue with the legendary @ucirvinelaw.bsky.social Prof. Dan Burk's final article (published posthumously). cc: @sluhealthlaw.bsky.social @slulaw.bsky.social

New out in @natgenet.nature.com - The bankruptcy of #23andMe put #human #genetic #data at risk of #enclosure. Under the new #23andMeResearchInstitute, data remain available. Read me, @jonathanmoreno.bsky.social et al on lessons for next time: www.nature.com/articles/s41... @ucirvine.bsky.social

Professor @jcontreras.bsky.social coauthored an article in @nature.com with @realjlo.bsky.social, Christopher R. Donohue, @jonathanmoreno.bsky.social, Ana Santos Rutschman, Joshua Sarnoff, @drsinhaesq.bsky.social + Thomas Stoeger about 23andMe + its database. www.nature.com/articles/s41...

cc: @slulaw.bsky.social @sluhealthlaw.bsky.social

🚨NEW🚨 in @jama.com: Combination-Only Approvals as a Barrier to Affordable #HIV Care jamanetwork.com/journals/jam... Glad to see it published on #WorldAIDSDay! An important reminder of the work that still needs to be done.

Just finished a terrific semester of Health Equity, Policy & Advocacy at @slulaw.bsky.social, an experiential law school class focused on the preparation of white papers and other deliverables for the City of St. Louis Department of Health and the St. Louis County Department of Public Health.

After a busy semester teaching 1L Torts (for the first time) to 81 (!!!) students, I remain optimistic about the future of the legal profession! "class photo" via Gemini, complete with Simon the pug and the arm sling I was using last week. Best of luck with finals!

Calling it a "clown show" or a "soap opera" seems to imply that there is no real-world impact. That it's just a performance. To be clear: these "theatrics" will have devastating consequences to FDA and its stakeholders that may take decades to overcome.

This really was an inspiring set of conversations. Thank you, @sbagen.bsky.social! #publichealth #healthlaw

This was a lot of fun. But I think we could do a caption contest with this photo.

Thought-provoking talk today by @umichlaw.bsky.social Professor @sbagen.bsky.social on his experiences in public service and his ideas for "Reconstructing the Public Health State" On behalf of @slulaw.bsky.social and @sluhealthlaw.bsky.social, thank you for joining us!

Happening today at noon: @sbagen.bsky.social @umichlaw.bsky.social will present "Reconstructing the Public Health State" as part of the @sluhealthlaw.bsky.social Distinguished Speaker Series!

Thrilled that my new piece with @drsinhaesq.bsky.social is out. We review different funding models for research and stress the importance of public funding for two reasons: (1) It can support non-profit-driven research, and (2) It can serve as a bulwark against corporate influence over science.

NEW with @medlawdan.bsky.social @sjquinney.bsky.social in Health Affairs Forefront: As An Alternative To Federal Research Funding, Private Investment Brings Significant Risks www.healthaffairs.org/content/fore... cc: @slulaw.bsky.social @sluhealthlaw.bsky.social

👇This important work wrt how surgeons deal with microaggressions in the workplace #MedSky #SurgSky

🚨NEW🚨 paper with Physician Just Equity colleagues in @acsjacs.bsky.social: Whether and How Surgeons Took Action Against Workplace Microaggression: Survey of ACS Members journals.lww.com/journalacs/a...

The Weight of Stigma: working draft now available on @SSRN, we welcome your feedback! papers.ssrn.com/sol3/papers....

#FireproofingTheFDA Panel 4 Moderator Prof. Robert Harrison (@sjquinney.bsky.social) is a @slulaw.bsky.social @sluhealthlaw.bsky.social alum! cc: @medlawdan.bsky.social